Oxford Asset Management’s Atara Biotherapeutics ATRA Stock Holding History

Oxford Asset Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,363	Closed	-$1.39M	–	306
2019 Q4	$1.39M	Buy	+3,363	New	+$1.16M	0.04%	640
2019 Q1	–	Sell	-615	Closed	-$534K	–	1653
2018 Q4	$534K	Buy	+615	New	+$571K	0.01%	1170
2016 Q1	–	Sell	-4,025	Closed	-$2.54M	–	794
2015 Q4	$2.54M	Buy	+4,025	New	+$3.04M	0.06%	350

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

Oxford Asset Management's ATRA Position: Q1 2020 in Review

Oxford Asset Management sold out of Atara Biotherapeutics (ATRA) in Q1 2020, closing a stake of 3,363 shares — an estimated $1.39M sold.

Oxford Asset Management first reported a position in ATRA in Q4 2015 and held it in 3 quarters. The position peaked at $2.54M in Q4 2015. 111 funds tracked by Wall St. Rank hold ATRA as of Q1 2020.

Oxford Asset Management reported no remaining Atara Biotherapeutics position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 3,363 Atara Biotherapeutics shares in Q1 2020, an estimated $1.39M.
Oxford Asset Management first reported a position in Atara Biotherapeutics in Q4 2015 and held it in 3 quarters.
Oxford Asset Management's Atara Biotherapeutics position peaked at $2.54M in Q4 2015.
111 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.